Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

GPNMB-directed CAR-T cell therapies for solid tumors.

Nature cancer·2026

Same author

Reductions in Immunoglobulin Levels, Atopic Disease, and Asthma Following CAR T-Cell Therapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026

Same author

Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations.

Molecular therapy. Oncology·2026

Same author

In vivo gene therapy with CAR-T cells.

Blood·2026

Same author

When tumor contact reshapes CAR-T cells.

The Journal of experimental medicine·2026

Same author

Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.

Science (New York, N.Y.)·2026

Same journal

Thymic cortical epithelial Psmb11-encoded β5t in mouse and human.

International immunology·2026

Same journal

Signaling and Transcriptional Control of Thymocyte Differentiation.

International immunology·2026

Same journal

17,18-epoxyeicosatetraenoic acid and its metabolite attenuate IL-33-induced airway inflammation involving group 2 innate lymphoid cells.

International immunology·2026

Same journal

FcμR enhances recall responses by promoting the generation of CD80+PD-L2+ memory B cells.

International immunology·2026

Same journal

Mitochondrial Transfer-Driven Immune Evasion in the Tumor Microenvironment.

International immunology·2026

Same journal

Granulocyte heterogeneity in immune-mediated and inflammatory diseases: Insights from single-cell transcriptomic analyses.

International immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric antigen receptor-modified T cells strike back.

Matthew J Frigault¹, Marcela V Maus²

¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Building 149, 13th Street, Room 7.219, Charlestown, Boston, MA 02129, USA.

International Immunology

|March 30, 2016

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR)-T-cell therapy engineers T cells to target cancer. While successful against CD19+ cancers, challenges remain in finding new targets and managing toxicities for broader applications.

Keywords:

T-cell therapy cellular immunotherapy chimeric antigen receptor clinical immunology gene therapy

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Mar 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Chimeric antigen receptors (CARs) are engineered T-cell receptors.
CARs combine antibody specificity with T-cell cytotoxic ability.
CAR-T therapy has shown significant success in CD19+ B-cell malignancies.

Purpose of the Study:

To review the basic structure and function of CARs.
To discuss the successes and challenges of CAR-T-cell therapy.
To explore new approaches for broader CAR-T-cell application in cancer treatment.

Main Methods:

Review of existing literature on CAR structure, function, and clinical trials.
Analysis of challenges in CAR-T-cell therapy, including target identification and toxicity management.
Exploration of novel strategies to enhance CAR-T-cell efficacy and overcome tumor microenvironment barriers.

Main Results:

CAR-T-cell therapy targeting CD19 has demonstrated remarkable efficacy in relapsed/refractory B-cell malignancies.
Understanding of CAR biology is still evolving.
Significant challenges persist, including identifying new targets, managing toxicities, and overcoming immunosuppression.

Conclusions:

CAR-T-cell therapy holds immense potential for treating various cancers.
Further research is crucial to address current limitations and expand its application.
Optimizing CAR design and therapeutic strategies is key to overcoming treatment resistance and improving patient outcomes.